Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 8/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.59 |
| ▸ | ACE | P12821 | 2/20 | 0.48 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.47 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30116346 | 0.99 | OPRD1 (0.59) | OPRD1OPRM1ACENPFFR1NPFFR2 | |
| SCHEMBL30533414 | 0.99 | OPRD1 (0.59) | OPRD1OPRM1ACENPFFR1NPFFR2 | |
| SCHEMBL30116348 | 0.97 | OPRD1 (0.57) | OPRD1OPRM1ACE | |
| SCHEMBL30439569 | 0.97 | OPRD1 (0.57) | OPRD1OPRM1ACE | |
| SCHEMBL29531591 | 0.96 | OPRD1 (0.57) | OPRD1OPRM1ACE | |
| SCHEMBL30503059 | 0.96 | OPRD1 (0.56) | OPRD1OPRM1ACENPFFR1NPFFR2 | |
| SCHEMBL30439746 | 0.96 | OPRD1 (0.56) | OPRD1OPRM1ACENPFFR1NPFFR2 | |
| SCHEMBL29392400 | 0.96 | OPRD1 (0.56) | OPRD1OPRM1ACENPFFR1NPFFR2 | |
| SCHEMBL30116357 | 0.96 | OPRD1 (0.56) | OPRD1OPRM1ACENPFFR1NPFFR2 | |
| SCHEMBL30116351 | 0.95 | OPRD1 (0.65) | OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116940370-A | Combination therapy of insulinotropic peptide and GLP-2 for preventing or treating short bowel syndrome | 韩美药品株式会社 | 2023-10-24 | — | — | CN | disclosed |
| CN-116635050-A | Novel triple agonists active on all of glucagon, GLP-1 and GIP receptors and uses thereof | 韩美药品株式会社 | 2023-08-22 | — | — | CN | disclosed |
| CN-116600831-A | Triple agonists or conjugates thereof active on all of glucagon, GLP-1 and GLP receptors for the treatment of neurodegenerative diseases | 韩美药品株式会社 | 2023-08-15 | — | — | CN | disclosed |
| CN-116437967-A | Pharmaceutical composition for preventing or treating bone diseases comprising triple agonists or conjugates thereof having activity on all of glucagon, GLP-1 and GLP receptors | 韩美药品株式会社 | 2023-07-14 | — | — | CN | disclosed |
| CN-116419766-A | Therapeutic use of long-acting conjugates of triple agonists acting on all of the glucagon, GLP-1 and GIP receptors against multiple sclerosis | 韩美药品株式会社 | 2023-07-11 | — | — | CN | disclosed |
| CN-116419765-A | GLP-1/GIP dual agonists, long acting conjugates thereof and pharmaceutical compositions comprising the same | 韩美药品株式会社 | 2023-07-11 | — | — | CN | disclosed |
| CN-116390769-A | Pharmaceutical composition for preventing or treating lupus-related diseases comprising glucagon/GLP-1/GIP triple agonist or long-acting conjugate thereof | 韩美药品株式会社 | 2023-07-04 | — | — | CN | disclosed |
| CN-115916238-A | Hyperlipemia preventing or treating composition containing glucagon/GLP-l/GIP receptor triple agonist or conjugate thereof and use method thereof | 韩美药品株式会社 | 2023-04-04 | — | — | CN | disclosed |
| CN-115811970-A | Liquid formulations of long-acting conjugates of glucagon, GLP-1 and GIP triple agonists | 韩美药品株式会社 | 2023-03-17 | — | — | CN | disclosed |
| CN-115803015-A | Liquid formulations of long-acting conjugates of glucagon derivatives | 韩美药品株式会社 | 2023-03-14 | — | — | CN | disclosed |
| CN-115776880-A | Liquid preparation | 韩美药品株式会社 | 2023-03-10 | — | — | CN | disclosed |
| CN-115697375-A | Pharmaceutical composition comprising GLP-2 derivatives or long-acting conjugates thereof for the prevention or treatment of mucositis induced by radiotherapy, chemotherapy or a combination thereof | 韩美药品株式会社 | 2023-02-03 | — | — | CN | disclosed |